valu usd unless otherwis note
see rel stabil big surpris
new ceo post call manag
view report better late never delay result
came thought reason guidanc includ
push pull continu look evid robust
growth chca deliv stabl perform
limit stock volatil still make tough argu materi
upsid chang outlook target
come away discuss manag includ
new ceo ewe roehrhoff unchang view surpris
continu deliv stabl perform per note
print link separ note post call link struggl
growth current valuat new ep slightli
higher impli modest compound-annual-growth-rate
valuat remain premium growth unreason
rel histor level us take aggress
stanc need see materi upsid forecast drive
better growth see yet leav three broad
still look better growth chca constant currenc
growth outlook bad remain
target segment like continu drive
premium valuat ev/ebitda gener rx gross
profit chci gross profit still make half
overal platform valuat comp materi lower
ii rx continu hold better given compani
credit two part first revenu growth
driven two larg gener launch
oper incom concentr quarter know gener proair
partner one believ action date reflect
ep known partner feel confid
launch appropri tri call gener
sector bottom manag guid stabl gross margin
remain focu
iii balanc sheet improv capit deploy go
becom opportun could drive upsid model per
discuss manag contribut guidanc
spend whether addit share repurchas debt reduct
model million debt reduct base histori
reason see type deploy may limit
next month manag work board determin
long-term strateg vision present street
includ long await decis gener busi
price prior trade day market close estimate unless otherwis note
stabl long-term outlook near-term uncertainti around
strateg outlook moder growth could lead
pressur valuat compani segment across brand
over-the-counter store brand rx pharma add diversif
see headwind across segment manag
need manag
driver thesi
chca growth like remain lower level
near term base busi eros like remain
chci add eu exposur howev focu remain
segment near-term headwind persist
gener rx remain biggest unknown sector
headwind persist high-margin natur
add potenti variabl ep line importantli
manag evalu whether deem segment
core
valuat remain premium growth
unreason rel histor level
upsid risk success break-up compani sale
drive premium asset acceler new launch
activ across over-the-counter rx fda approv new larg
downsid risk slowdown core chca health
longer expect unexpect meaning
competit entri us store brand over-the-counter new unexpect
rx gener competit emerg back acceler
upcom potenti catalyst result strateg review
unexpect new launch potenti
bloomberg capit market estim upside/downside/target
base-cas scenario see stock impli
price-to-earnings ep
flat low-single-digit growth chca consolid
flat oper margin across platform spend
debt pay-down excess cash share repurchas
prior price target base price-to-earnings ev/ebitda
closer sotp valu come
upsid case scenario see stock impli
price-to-earnings ep
mid-single-digit better organ revenu growth
oper margin expans across platform
debt pay-down excess cash share repurchas
downsid scenario see stock impli
price-to-earnings pro forma ep
growth core consum health segment erod
neg oper margin trend reflect slowdown
revenu modestli higher cost base
exhibit segment build
 segment build healthcar guid gross distribut oper oper sale growth sg guid adj oper marginsal mix profit mix incom mix healthcar guid gross distribut oper oper sale growth legaci omega businessdistribut sg guid adj oper marginsal mix profit mix incom mix exhibit segment build continu
 segment build guid growth gener proair launch bp gm roughli epsdistribut oper oper sale growth proair help support modest growth sg guid net salesoper guid adj oper marginsal mix profit mix incom mix corpor cost across platform exhibit forecast
 incom healthcar guid billionconsum healthcar guid billionprescript guid specialti sciencesroyalti soldtot revenu guid billion growth y-i total gross profit gross guid net salessg guid dsg net salesoper incom guid adj op incom billion oper cy op incom weight incom guid millionincom tax provis incom guid adj effect tax ratenet incom ep non-gaap guid share fulli dilut share guid million sharesebitda ebitda analysi net margin guid net guid dsg net salesoper guid adj op incom billioninterest expens cy op incom weight guid adj effect tax ratecash net incom pharmaceuticals/specialti
price target base blend price-to-earnings ev/ebitda multipl use pro
forma estim cy assum multipl respect target
assum trade lower end trough year bolster
temporari premium level impli ev/ebitda basi given structur lower
risk rate price target
organ revenu growth consum health segment soften due weaker
expect over-the-counter market growth greater expect price eros
delay fda approv gener drug applic result declin revenu and/
margin rx segment
unexpect meaning competit entri us store brand over-the-counter rx busi
lead store-brand over-the-counter manufactur us market share compani
also particip pharmaceut market domest intern
omega deal ad ex-u exposur often compar larg global
manufactur realiti direct comp given diversifi busi model
encompass consum healthcar brand consum healthcar rx compani
acquir brought lower tax structur royalti stream tysabri sold
royalti pharma set platform intern expans
